Had a lot of great conversations reporting on this the last few months -- Are PD-1xVEGF bispecifics being tested in the wrong kinds of cancer? endpoints.news/are-pd-1xveg...

Had a lot of fun digging into the science about how this new startup wants to treat food allergies endpoints.news/excellergy-d...

Subcutaneous Keytruda approved in solid tumors endpoints.news/merck-wins-a...

The Fed cut interest rates by a quarter point. How much will it move the needle for biotech? endpoints.news/federal-rese...

Pfizer has a VEGF bispecific strategy. And it’s very different than Summit’s endpoints.news/pfizer-has-a...

Summit plays defense for the first time as questions loom over Phase 3 lung cancer readouts endpoints.news/summit-plays...

A British mitochondrial startup wants to break ground in ALS and Parkinson's. It has £50M to try endpoints.news/mitochondria...

Summit says long-awaited data in Western patients are a success. But they come with caveats endpoints.news/wclc25-summi...

SubQ Leqembi approved endpoints.news/fda-approves...

A recent FDA approval was seen as a bellwether for Alnylam. Now its sales are through the roof. endpoints.news/alnylam-shar...

Breaking from @drewsnews.bsky.social: Vinay Prasad is out at FDA endpoints.news/vinay-prasad...

A small biotech's breast cancer drug more than tripled patient outcomes in a Phase 3 trial, putting it in position to displace medicines from Novartis and Roche. endpoints.news/celcuity-pos...

FDA is holding an Expert Panel on the use of SSRIs during pregnancy this morning, but participants have long questioned antidepressant use endpoints.news/the-fdas-new...

Sat down virtually with Arvinas CEO John Houston about his announced retirement this morning, where we talked about PROTACs, the company's sliding stock price and what might happen with their Pfizer partnership endpoints.news/retiring-arv...

🍨🍨🍨 from Andy

Another cancer drug approval coming weeks ahead of the deadline www.fda.gov/drugs/resour...

One of my favorite Endpoints traditions is our annual look at the LGBTQ+ leaders in biopharma. We've got 13 awesome profiles this year, be sure to give it a read. And props to @kylelahucik.bsky.social for organizing it once again! endpoints.news/biopharma-le...

Saturday AM #ASCO25 news! Trodelvy+Keytruda "practice-changing" data: endpts.com/asco25-gilea... Pfizer PROTAC no better than oral SERDs: endpts.com/asco25-arvin... Enhertu extends life by 3 months in stomach cancer: endpts.com/asco25-enher... Early data from Immatics: endpts.com/asco25-immat...

Summit blew up my morning 🫠🫠🫠 endpts.com/summits-disa...

Robert F. Kennedy Jr., the health secretary, posted photos on Sunday of himself and his grandchildren swimming in a contaminated Washington creek where swimming is not allowed because it is used for sewer runoff.

Best Chicago controversy of the new Pope is the Cubs trying to lay claim to him and his brother having to speak up to clear up that he's a Sox fan. blockclubchicago.org/2025/05/08/p...

I spoke to some folks yesterday about Vinay Prasad’s appointment as director of CBER and what it means for biopharma. endpts.com/vinay-prasad...

Bristol Myers Squibb’s schizophrenia drug Cobenfy failed a Phase 3 study in the adjunctive setting, the company announced Tuesday afternoon. endpts.com/bristol-myer...

Most people haven’t heard of this test, which is available in the US. It accurately predicts Alzheimer’s (not just if there’s a risk, but when). It is modulated by exercise and likely other lifestyle factors. Here’s (almost) everything we know about it erictopol.substack.com/p/the-breakt...

Johnson & Johnson CEO Joaquin Duato subtly but assertively criticized President Donald Trump's plans for pharmaceutical tariffs, saying tax policy is a better way to onshore US drug manufacturing. endpts.com/jj-ceo-chide...

Pharma-specific tariffs inched closer after the Trump administration confirmed that it launched a 232 probe. That investigation actually began two weeks ago, on April 1. endpts.com/trump-drug-t...

FDA commissioner Marty Makary wants to phase out animal testing and replace it with organoids, lab-grown cultures of human cells that can mimic and recreate organs. But the process may take longer than the 3-5 year timeline he proposed. Story w/@scienceboss.bsky.social: endpts.com/fda-unveils-...

Really enjoyed this conversation with Johan Luthman, be sure to give it a read

The stock market meltdown is raising more questions for an already beleaguered biotech industry. endpts.com/as-stock-mar...

SCOOP: New FDA commissioner Martin Makary was sworn in Friday before HHS tried to push Peter Marks out, knew it was going to happen and did not stop it. #healthpolicy #biosky #medsky insights.citeline.com/pink-sheet/g...

New: Peter Marks' ouster at the FDA has rattled biotech stocks and comes as the market was already wobbly. w/@drewsnews.bsky.social and @kylelahucik.bsky.social endpts.com/biotech-mark...

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic Important story from @scienceboss.bsky.social: endpts.com/covid-resear...

This afternoon, the FDA approved a new RNAi treatment for hemophilia from Sanofi. Patients with either hemophilia A or B will be able to take it with or without Factor inhibitors. The average price per year is $642,000. endpts.com/fda-approves...

The FDA approved the first treatment for a rare disease called Prader-Willi syndrome, where a genetic mutation causes patients to experience insatiable hunger. There was no immediate info on pricing. endpts.com/fda-approves...

A small cap biotech developing radiopharmaceutical therapies for cancer is holding an investor event at Mar-a-Lago on Wednesday. endpts.com/why-did-radi...

A pie graph worth keeping in mind as the NIH budget plummets jamanetwork.com/journals/jam... for 356 new FDA drugs approved

Alnylam hopes its broad ATTR-CM label can give Amvuttra an edge in heart disease endpts.com/alnylam-hope...

New from me: Ahead of an FDA decision expected before this weekend, Alnylam faces the big question: Can it make money? endpts.com/ahead-of-fda...

A teenage boy who received Sarepta’s Duchenne muscular dystrophy gene therapy Elevidys died from liver failure. endpts.com/sixteen-year...

Gift link. www.theatlantic.com/health/archi...

Trimtech Therapeutics, which raised $31M on Wednesday, is using technology designed to recruit the body’s immune system to break down large protein aggregates seen in diseases like Alzheimer’s and Huntington’s. Pfizer and Eli Lilly invested in the company's seed round. endpts.com/lilly-pfizer...

“We’re not going to harm our children or [risk] the potential to harm our children so that we can save yours,” says the mother of an unvaccinated Texas child who contracted measles. Her 7-year-old son recovered. But an otherwise healthy unvaccinated 6-year-old died of measles 80 miles away.

🏳️‍🌈 It's time to celebrate and recognize the trailblazers in biopharma. We're now accepting nominations for our annual LGBTQ+ Leaders report, let's honor those who are paving the way for inclusivity and innovation. #LGBTQinBiopharma endpts.com/endpoints-lg...

NEW: Bill Anderson left Roche in 2023 to take one of the most difficult jobs in the corporate world — the CEO of Bayer I recently sat down with Anderson to see how it's going. Here's my latest deep dive into a big question: Can he save Bayer? endpts.com/bayer-ceo-bi...

Evidence that Alzheimer’s (and other neurodegenerations?) might have a lot to due with early formation of RNA G-quadraplexes. Which is not where we’ve generally been looking!

Important story from @elaineywchen.bsky.social Some patients in trials for new obesity drugs are losing too much weight, as industry pushes for ever more powerful medicines www.statnews.com/2025/02/20/t...

The strong launch for BridgeBio's rare heart disease drug Attruby continued Thursday as the company reported new prescription figures that surpassed even the most optimistic forecasts. $BBIO +6% endpts.com/bridgebios-h...

Cool story from @scienceboss.bsky.social about the future of CRISPR, and he'll have more coming. endpts.com/biotech-is-s...

Biopharma companies and CEOs are keeping their heads down at their own peril. They should speak up about what’s happening to the NIH and other science agencies before it’s too late. Silence gives consent. And no one should consent to this.

If you missed any of RFK Jr.'s hearing today, Endpoints watched and live blogged the whole thing, which you can find here ⬇️ endpts.com/kennedy-hear...